Response by Andreas et al to Letter Regarding Article, “Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot Trial”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
We thank Heinrich-Nols and Kreuzer for their valuable and very detailed response regarding the indication of dabigatran, its dosing regimen, and relevant considerations regarding monitoring of anticoagulation. We had to shorten our initial article significantly and were not able to address all points regarding dabigatran dosing and management.1
The dose was chosen in 2010 according to the approved indication at that time, which was the primary prevention of …